Silver dihydrogen citrate

Drug Profile

Silver dihydrogen citrate

Alternative Names: Axenohl; SDC

Latest Information Update: 16 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PURE Bioscience
  • Developer FTA Bioscience; PURE Bioscience
  • Class
  • Mechanism of Action DNA inhibitors; Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acne vulgaris; Bacterial vaginosis; Onychomycosis; Tinea pedis

Most Recent Events

  • 03 Aug 2010 Pharmacodynamics data from a preclinical trial in onychomycosis and tinea pedis released by PURE Bioscience
  • 03 Jul 2008 Silver dihydrogen citrate licensed to FTA Therapeutics in USA
  • 03 Jul 2008 Silver dihydrogen citrate is no longer licensed to Therapeutics Incorporated in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top